Berenberg Bank reaffirmed their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a report published on Tuesday morning. The firm currently has a GBX 1,835 ($24.74) price objective on the stock.

Several other research analysts have also issued reports on GSK. UBS AG set a GBX 1,600 ($21.57) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research report on Monday, May 29th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.62) price target on shares of GlaxoSmithKline plc and gave the stock a buy rating in a research report on Tuesday, August 8th. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research report on Thursday, September 14th. HSBC Holdings plc restated a buy rating and issued a GBX 1,970 ($26.56) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, September 13th. Finally, Deutsche Bank AG set a GBX 1,610 ($21.71) price target on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research report on Tuesday, August 8th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of GBX 1,698.52 ($22.90).

Shares of GlaxoSmithKline plc (LON GSK) opened at 1472.50 on Tuesday. The firm’s market cap is GBX 71.98 billion. The company has a 50 day moving average price of GBX 1,503.38 and a 200-day moving average price of GBX 1,606.97. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,745.56.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/22/glaxosmithkline-plc-gsk-earns-buy-rating-from-berenberg-bank.html.

The business also recently announced a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other news, insider Patrick Vallance bought 861 shares of the stock in a transaction on Friday, July 14th. The stock was purchased at an average price of GBX 1,618 ($21.81) per share, with a total value of £13,930.98 ($18,782.50). Also, insider Manvinder Singh Banga bought 2,267 shares of the stock in a transaction on Wednesday, July 26th. The stock was purchased at an average cost of GBX 1,599 ($21.56) per share, with a total value of £36,249.33 ($48,873.30). Insiders purchased 3,152 shares of company stock worth $5,055,023 over the last 90 days.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.